In This Article:
-
Company today announced a major strategic step forward as it explores new growth avenues
-
Artificial Intelligence (AI) and Quantum Computing industries represent multi-trillion dollar market opportunities1,2
-
Company is committed to maximize shareholder value through evaluation of strategic options
BALTIMORE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics would like to update its shareholders that has initiated a process to explore strategic alternatives to maximize shareholder value. The Company will continue to pursue its existing biopharma lines of business while evaluating a range of strategic options to maximize value for its shareholders. The business fields of quantum computing and AI are seen as the next frontier in emerging technologies, and have quickly developed into multi-billion dollar industries.
Aitan Zacharin, Chief Executive Officer, had this to say, “There have been a number of companies focused on developing these cutting edge technologies who have approached GCAN expressing interest in a potential merger, and as part of our fiduciary obligation to our shareholders we will explore these options. We look forward to updating our shareholders with continued developments.”
As part of the evaluation process GCAN will explore potential strategic alternatives that may include, but are not limited to a sale, merger, strategic business combination or other transaction. The Company cannot assure that its exploration will result in a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. The Company has not set a timetable for completion of the evaluation process. GCAN will make further announcements in accordance with its ongoing disclosure obligations and pursuant to applicable laws and regulations.
ENDS
For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact info@gcanrx.com. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.
1 https://www.mckinsey.com/featured-insights/the-rise-of-quantum-computing
2 https://www.bloomberg.com/company/press/generative-ai-to-become-a-1-3-trillion-market-by-2032-research-finds/
About Greater Cannabis Company: The Greater Cannabis Company (OTC: GCAN), (“GCANRx” or the “Company”) is a publicly traded clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. GCANRx’s mission is to bring its products to the global market for the benefit of patients seeking better solutions for their unmet medical needs.